menu
    • menu
    [{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"11","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"InCor Heart Institute | Hospital Santa Marcelina | Prevent Senior Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ InCor Heart Institute | Hospital Santa Marcelina | Prevent Senior Institute","highestDevelopmentStatusID":"7","companyTruncated":"Azidus \/ InCor Heart Institute | Hospital Santa Marcelina | Prevent Senior Institute"},{"orgOrder":0,"company":"Azidus","sponsor":"Boya Bio Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BRAZIL","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Boya Immunoglobulin","moa":"IgG","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Boya Bio Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Boya Bio Pharmaceutical Group"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BRAZIL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Immunoglobulins||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Azidus","sponsor":"Cellavita","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BRAZIL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Dental Pulp Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Cellavita","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Cellavita"},{"orgOrder":0,"company":"Azidus","sponsor":"Cellavita | Hospital Vera Cruz","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Cellavita | Hospital Vera Cruz","highestDevelopmentStatusID":"8","companyTruncated":"Azidus \/ Cellavita | Hospital Vera Cruz"},{"orgOrder":0,"company":"Azidus","sponsor":"Cellavita","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BRAZIL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Cellavita","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Cellavita"},{"orgOrder":0,"company":"Azidus","sponsor":"SENAI CIMATEC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RNA MCTI CIMATEC HDT Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ SENAI CIMATEC","highestDevelopmentStatusID":"8","companyTruncated":"Azidus \/ SENAI CIMATEC"}]

    Find Clinical Drug Pipeline Developments & Deals by Azidus

    Menu

    Azidus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

                            Details : Nitazoxanide is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2025

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Boya Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Boya Bio Pharmaceutical Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety and Pharmacokinetics of Boya IVIG

                            Details : Boya Immunoglobulin is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Primary Immunodeficiency Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 29, 2023

                            Lead Product(s) : Boya Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Boya Bio Pharmaceutical Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal Stem Cell,Human Dental Pulp Stem Cell

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Cellavita

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of NestaCell® in Huntington's Disease

                            Details : NestaCell (Human Dental Pulp Stem Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Huntington Disease.

                            Product Name : NestaCell

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 24, 2023

                            Lead Product(s) : Mesenchymal Stem Cell,Human Dental Pulp Stem Cell

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Cellavita

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Intravenous Immune Globulin,Immune Globulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

                            Details : IVIG (Intravenous Immune Globulin) is a Antibody-protein Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Primary Immunodeficiency Diseases.

                            Product Name : IVIG

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Intravenous Immune Globulin,Immune Globulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

                            Details : Leronlimab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Signs and Symptoms, Digestive.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 02, 2022

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA MCTI CIMATEC HDT Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : SENAI CIMATEC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine

                            Details : RNA MCTI CIMATEC HDT Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 15, 2022

                            Lead Product(s) : RNA MCTI CIMATEC HDT Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : SENAI CIMATEC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients

                            Details : Nitazoxanide is a Antibiotic drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2020

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19

                            Details : Nitazoxanide is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2020

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With ...

                            Details : Nitazoxanide is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2020

                            Lead Product(s) : Nitazoxanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Farmoquimica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed

                            Azidus

                            Brazil arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : InCor Heart Institute | Hospital Santa Marcelina | Prevent Senior Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients

                            Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 20, 2020

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : InCor Heart Institute | Hospital Santa Marcelina | Prevent Senior Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth